Numinus Wellness (STU:LR23) Research & Development: €0.00 Mil (TTM As of May. 2025)


STU:LR23 Numinus Wellness Inc STU:LR23
10 GF Score
Price €0.03
View Full Analysis

What is Numinus Wellness Research & Development?

Numinus Wellness STU:LR23 10 Research & Development is €0.00 Mil as of May. 2025. GuruFocus rates STU:LR23 with a GF Score™ of 10/100.

Research & Development is the aggregate amount of research and development expenses during the year. Numinus Wellness's Research & Development for the three months ended in May. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in May. 2025 was €0.00 Mil.

Numinus Wellness  (STU:LR23) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Numinus Wellness Research & Development Related Terms

Numinus Wellness Research & Development Historical Data

* Premium members only.

The historical data trend for Numinus Wellness's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Numinus Wellness Research & Development Chart

Numinus Wellness Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Research & Development
Get a 7-Day Free Trial 0.12 0.95 1.44 0.80 0.02

Numinus Wellness Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:LR23
10GF Score
Numinus Wellness Inc STU:LR23
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Numinus Wellness Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in May. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Numinus Wellness (STU:LR23) has a Research & Development of €0.00 Mil as of May. 2025. Research and development expense is the total cost for research and development activities. View historical data on Numinus Wellness and its competitors.
Is Numinus Wellness' Research & Development too high?
Numinus Wellness' current Research & Development is €0.00 Mil. Overall, Numinus Wellness has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Numinus Wellness' Research & Development compare to HLYK and SYRA?
Numinus Wellness' Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Numinus Wellness and its competitors. Numinus Wellness's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numinus Wellness stock overvalued right now?
Numinus Wellness (STU:LR23) has a current Research & Development of €0.00 Mil. The current Research & Development is €0.00 Mil. Numinus Wellness' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Numinus Wellness (STU:LR23), the current Research & Development is €0.00 Mil as of May. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Numinus Wellness Business Description

Address 801 - 33 Water Street, Vancouver, BC, CAN, V6B 1R4
Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.
10GF Score

Get the complete analysis for STU:LR23

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price